Identifying hypocoagulable states with a modified global assay of overall haemostasis potential in plasma

To test the sensitivity of the global assay of overall haemostasis potential (OHP) in detecting hypocoagulation, the OHP was assayed in plasma containing exogenous thrombin (0.04 IU/ml), tissue-plasminogen activator (330 ng/ml), Ca2+ and a platelet reagent. Commercial plasmas with factor II, V, VIII, IX, X, XI, XII or VII deficiency were mixed with normal plasma in different proportions to imitate different severities. Samples from patients with haemophilia and factor XII deficiency were also examined. No clot was found in the absence of factor II/factor X, indicating that the tiny dose of thrombin worked solely as a trigger for the intrinsic pathway activation. Changed levels of the investigated coagulants, apart from factor XII, influenced the outcome. OHPs were decreased in patients with haemophilia but were unchanged or even increased in those with factor XII deficiency. This modified OHP method may therefore be useful for estimating the bleeding tendency in haemophilic patients and to find suitable doses and intervals for prophylactic treatment. It may also be of use in investigations of the effect of antifibrinolytic drugs as well as for identifying a thrombotic tendency in patients with factor XII deficiency. For detection of other coagulation factor deficiencies, our investigations with the commercial plasmas suggest that the OHP assay is also valuable, especially when the intrinsic pathway of the coagulation cascade is impaired.

[1]  M. Blombäck,et al.  Overall hemostatic potential (OHP) assay—a possible tool for determination of prothrombotic pattern in FXII deficiency , 2004, Journal of thrombosis and haemostasis : JTH.

[2]  M. Blombäck,et al.  Increased hemostasis potential persists in women with previous thromboembolism with or without APC resistance , 2003, Journal of thrombosis and haemostasis : JTH.

[3]  B. Sørensen,et al.  Potential role of the dynamic properties of whole blood coagulation in assessment of dosage requirements in haemophilia , 2003, Haemophilia : the official journal of the World Federation of Hemophilia.

[4]  M. Blombäck,et al.  The role of recombinant factor VIIa (FVIIa) in fibrin structure in the absence of FVIII/FIX , 2003, Journal of thrombosis and haemostasis : JTH.

[5]  R. al Dieri,et al.  Thrombin Generation Measurement in Factor VII-Depleted Plasmas Compared to Inherited Factor VII-Deficient Plasmas , 2003, Pathophysiology of Haemostasis and Thrombosis.

[6]  D. Monroe,et al.  Platelets and thrombin generation. , 2002, Arteriosclerosis, thrombosis, and vascular biology.

[7]  M. Blombäck,et al.  Total thrombin‐activatable fibrinolysis inhibitor (TAFI) antigen and pro‐TAFI in patients with haemophilia A , 2001, Haemophilia : the official journal of the World Federation of Hemophilia.

[8]  M. Blombäck,et al.  A simple and rapid laboratory method for determination of haemostasis potential in plasma. II. Modifications for use in routine laboratories and research work. , 2001, Thrombosis research.

[9]  D. Monroe,et al.  A Cell-based Model of Hemostasis , 2001, Thrombosis and Haemostasis.

[10]  F. Rosendaal,et al.  Definitions in Hemophilia , 2001, Thrombosis and Haemostasis.

[11]  K. Mann,et al.  Novel, Bedside, Tissue Factor–Dependent Clotting Assay Permits Improved Assessment of Combination Antithrombotic and Antiplatelet Therapy , 2000, Circulation.

[12]  J. Badimón,et al.  Transfer of tissue factor from leukocytes to platelets is mediated by CD15 and tissue factor. , 2000, Blood.

[13]  M. Blombäck,et al.  A laboratory method for determination of overall haemostatic potential in plasma. I. Method design and preliminary results. , 1999, Thrombosis research.

[14]  P. Mannucci,et al.  Rare Coagulation Disorders , 1999, Thrombosis and Haemostasis.

[15]  H. Büller,et al.  Reduction of contact activation related fibrinolytic activity in factor XII deficient patients. Further evidence for the role of the contact system in fibrinolysis in vivo. , 1991, The Journal of clinical investigation.

[16]  M. Blombäck,et al.  Oral surgery in patients with hereditary bleeding disorders. A survey of treatment in the Stockholm area (1974-1985). , 1989, International journal of oral and maxillofacial surgery.

[17]  C. Mannhalter,et al.  Factor XII activity and antigen concentrations in patients suffering from recurrent thrombosis , 1987 .

[18]  J J Pisano,et al.  Hageman factor fragment inhibitor in corn seeds: purification and characterization. , 1980, Thrombosis research.

[19]  H. Hemker,et al.  The Role of Factor XI in Thrombin Generation Induced by Low Concentrations of Tissue Factor , 2001, Thrombosis and Haemostasis.